Skip to main content
Equibles

Diametric Capital, LP

Position in REPL — Replimune Group, Inc.

CIK 1719087 BOSTON, MA
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$555,559
+$346,059 QoQ
Shares Held
50,186
+0.4% QoQ
Ownership
0.053%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#77
of 199 holders
Holding Since
Sep 2025
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Diametric Capital, LP holds $91,993,189 across 32 Biotechnology names. REPL ranks #15 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 PGEN
Precigen, Inc.
 9,269,926 $52,838,578
2 QURE
uniQure N.V.
 197,242 $9,084,966
3 ABVX
Abivax S.A.
 51,903 $6,916,593
4 ABEO
Abeona Therapeutics Inc.
 755,021 $4,666,029
5 ZVRA
Zevra Therapeutics, Inc.
 231,465 $3,319,208
6 UNCY
Unicycive Therapeutics, Inc.
 374,132 $1,754,679
7 ANAB
Anaptysbio, Inc
 16,868 $1,138,590
8 NKTR
Nektar Therapeutics
 15,967 $1,114,656

All Filings in REPL

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $555,559 50,186
2025-09-30 $209,500 50,000